JP2002522385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522385A5 JP2002522385A5 JP2000563275A JP2000563275A JP2002522385A5 JP 2002522385 A5 JP2002522385 A5 JP 2002522385A5 JP 2000563275 A JP2000563275 A JP 2000563275A JP 2000563275 A JP2000563275 A JP 2000563275A JP 2002522385 A5 JP2002522385 A5 JP 2002522385A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- divalent
- here
- embedded image
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 230000002452 interceptive effect Effects 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- -1 indole compound Chemical class 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 239000000651 prodrug Chemical class 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012453 solvate Chemical class 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- SYVIXRHVBKSIRN-UHFFFAOYSA-N CCc([n](Cc1ccccc1)c1c2c(OCC(O)=O)ccc1)c2NC(N)=O Chemical compound CCc([n](Cc1ccccc1)c1c2c(OCC(O)=O)ccc1)c2NC(N)=O SYVIXRHVBKSIRN-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9511498P | 1998-08-03 | 1998-08-03 | |
| US60/095,114 | 1998-08-03 | ||
| PCT/US1999/017459 WO2000007590A1 (en) | 1998-08-03 | 1999-08-02 | INDOLE sPLA2 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002522385A JP2002522385A (ja) | 2002-07-23 |
| JP2002522385A5 true JP2002522385A5 (enExample) | 2006-07-27 |
Family
ID=22249768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563275A Withdrawn JP2002522385A (ja) | 1998-08-03 | 1999-08-02 | インドールｓＰＬＡ２インヒビター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6451839B1 (enExample) |
| EP (1) | EP1100492B1 (enExample) |
| JP (1) | JP2002522385A (enExample) |
| AT (1) | ATE326963T1 (enExample) |
| CA (1) | CA2338855A1 (enExample) |
| DE (1) | DE69931496T2 (enExample) |
| ES (1) | ES2263283T3 (enExample) |
| WO (1) | WO2000007590A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2338727A1 (en) * | 1998-08-03 | 2000-02-17 | Edward David Mihelich | Indole spla2 inhibitors |
| EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| EP1349836B1 (en) * | 2000-12-18 | 2006-06-14 | Eli Lilly And Company | Tetracyclic derivatives as spla2 inhibitors |
| US6992100B2 (en) | 2001-12-06 | 2006-01-31 | Eli Lilly And Company | sPLA2 inhibitors |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| WO2004093872A1 (en) * | 2003-03-31 | 2004-11-04 | Eli Lilly And Company | 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors |
| EP1747014A4 (en) * | 2004-05-03 | 2007-09-12 | Ilypsa Inc | MODULATION OF LYSOPHOSPHATIDYLCHOLINE AND TREATMENT OF CONDITIONS INDUCED BY A DIET |
| US20090306171A1 (en) * | 2005-11-03 | 2009-12-10 | Han-Ting Chang | Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors |
| JP2009514893A (ja) | 2005-11-03 | 2009-04-09 | イリプサ， インコーポレイテッド | 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用 |
| AU2006311765A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| AU2006311851A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Azaindole compounds and use thereof as phospholipase-A2 inhibitors |
| EP1948604A1 (en) * | 2005-11-03 | 2008-07-30 | Ilypsa, Inc. | Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| EP2211425A1 (en) | 2009-01-23 | 2010-07-28 | MTA S.p.A. | Female electrical terminal |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
| US5132319A (en) * | 1991-03-28 | 1992-07-21 | Merck Frosst Canada, Inc. | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis |
| GB9204365D0 (en) * | 1992-02-28 | 1992-04-08 | Pfizer Ltd | Indoles |
| WO1994012475A1 (en) * | 1992-11-27 | 1994-06-09 | Yason S.R.L. | Indole derivative having prolonged immunostimulating activity and pharmaceutical compositions therefrom |
| IL109311A0 (en) | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| US6252084B1 (en) * | 1994-03-15 | 2001-06-26 | Eli Lilly And Company | 1H-indole-3-acetamide sPLA2 inhibitors |
| MX9501608A (es) | 1994-04-01 | 1997-02-28 | Lilly Co Eli | 1h-indol-3-glioxilamidas inhibidoras de spla2. |
| CA2310249A1 (en) * | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
-
1999
- 1999-08-02 DE DE69931496T patent/DE69931496T2/de not_active Expired - Fee Related
- 1999-08-02 CA CA002338855A patent/CA2338855A1/en not_active Abandoned
- 1999-08-02 US US09/762,069 patent/US6451839B1/en not_active Expired - Fee Related
- 1999-08-02 AT AT99938936T patent/ATE326963T1/de not_active IP Right Cessation
- 1999-08-02 EP EP99938936A patent/EP1100492B1/en not_active Expired - Lifetime
- 1999-08-02 ES ES99938936T patent/ES2263283T3/es not_active Expired - Lifetime
- 1999-08-02 WO PCT/US1999/017459 patent/WO2000007590A1/en not_active Ceased
- 1999-08-02 JP JP2000563275A patent/JP2002522385A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002522385A5 (enExample) | ||
| WO2005041899A3 (en) | Orally available sphingosine 1-phosphate receptor agonists and antagonists | |
| DK1023308T3 (da) | Inhibitorer af nukleosidmetabolisme | |
| WO2001087845A3 (en) | N-containing heterocyclic compounds and their use as 5-ht antagonists | |
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| JP2002502874A5 (enExample) | ||
| TW200519088A (en) | Aryl or heteroaryl amide compounds | |
| JP2002522386A5 (enExample) | ||
| JP2002534523A5 (enExample) | ||
| JP2004501940A5 (enExample) | ||
| WO2001009103A3 (en) | Imidazole antiproliferative agents | |
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JP2006511484A5 (enExample) | ||
| RU2005138719A (ru) | Новые бисамидатные фосфонатные пролекарства | |
| JP2002519325A5 (enExample) | ||
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| DK0791006T3 (da) | Polyanioniske benzylglylcosider som inhibitorer af proliferation af glatte muskelceller | |
| WO2004089366A8 (en) | Bicyclic compounds as nr2b receptor antagonists | |
| JP2002527414A5 (enExample) | ||
| TW200611687A (en) | Pharmaceutical compositions used for immunosuppressant | |
| KR900018074A (ko) | N-헤테로아릴-4-퀴놀린아민, 이의 제조방법 및 약제로서의 이의 용도 | |
| JP2004518658A5 (enExample) | ||
| EA200701780A1 (ru) | Противоопухолевое средство | |
| CA2589438C (en) | Treatment of inflammatory bowel disease |